Iran Press/Iran News: Mohammadi emphasized that Iranian researchers have worked extensively in the field, submitting tissue cell production requests to the FDA for over a decade. While cell therapy products are relatively new globally, with only a handful of countries in the field, Iran has now accelerated its licensing process, issuing four production permits this year alone.
The FDA head noted that these achievements, building upon past successes in chemical and biological pharmaceuticals, represent a major step in treating specific diseases through advanced methods such as gene and cell therapy. Furthermore, Mohammadi highlighted the significant potential for export revenue from these innovative products, positioning Iran as a key player in this emerging medical field.
Cell therapy is a medical approach that uses live stem cells to restore damaged cell functions, supporting disease recovery as healthy cells continue their activity. Various cell types are employed in this therapy, including hematopoietic (blood-forming) stem cells, skeletal muscle stem cells, neural stem cells, and other specialized cells such as lymphocytes, dendritic cells, and pancreatic islet cells, each tailored to target specific structural and functional needs in the body.
206
Read More:
Iran Innovates with Bipolar Surgical Scissors, Reducing Costs and Surgery Time
